Marinov J, Koubek K, Starý J
Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Neoplasma. 1993;40(6):355-8.
In 72 patients with blood malignancies (leukemias), the expression and distribution of the "B-lineage" antigen CD38, was analyzed, individually and in combination with CD19, CD10, HLA-DR, CD13, CD14, CD33, CDw65, CD2 and CD7. The expression of CD38 on the surface of leukemic cells was totally different from its expression on normal hematopoietic cells. Its positivity in myeloid malignancies was as follows: In patients with acute myeloid leukemia in 21/28 cases-75% (probability of expression 0.68 +/- 0.2, p < 0.05) and in patients with chronic myeloid leukemia in 4/6 cases-66%. In lymphoproliferative malignancies the CD38 antigen was expressed as follows: In patients with acute non-T lymphoblastic leukemia in 12/16 cases-75% (probability of expression 0.7 +/- 0.2, p < 0.05) and in patients with chronic B lymphocytic leukemia in 6/8 cases-75%. CD38 was also found positive in patients with acute mixed lineage leukemia.
对72例血液系统恶性肿瘤（白血病）患者，分别单独以及联合CD19、CD10、HLA - DR、CD13、CD14、CD33、CDw65、CD2和CD7，分析了“B系”抗原CD38的表达和分布情况。白血病细胞表面CD38的表达与正常造血细胞上的表达完全不同。其在髓系恶性肿瘤中的阳性率如下：急性髓系白血病患者中21/28例（75%，表达概率0.68±0.2，p<0.05），慢性髓系白血病患者中4/6例（66%）。在淋巴细胞增殖性恶性肿瘤中，CD38抗原的表达情况如下：急性非T淋巴细胞白血病患者中12/16例（75%，表达概率0.7±0.2，p<0.05），慢性B淋巴细胞白血病患者中6/8例（75%）。在急性混合谱系白血病患者中也发现CD38呈阳性。
